Gastrointestinal Cancers Symposium (ASCO GI) | Conference

Pembrolizumab Induces Antitumor Activity in Previously Untreated HCC

January 18th 2021

Single-agent pembrolizumab demonstrated durable antitumor activity among patients with treatment-naïve hepatocellular carcinoma, suggesting that the checkpoint inhibitor may have additional utility in this space, according to findings from a phase 2 trial presented during the 2021 Gastrointestinal Cancers Symposium.

Second-Line Pembrolizumab Has Maintained Survival Benefit in Advanced HCC

January 18th 2021

January 17, 2021 - Pembrolizumab demonstrated maintained numerical improvements in overall survival and progression-free survival compared with placebo in patients with previously treated advanced hepatocellular carcinoma.

Atezolizumab/Bevacizumab Combo Maintains Survival Advantage in Advanced HCC

January 17th 2021

January 17, 2021 - The combination of atezolizumab and bevacizumab continued to display improved survival compared with sorafenib in previously untreated patients with advanced hepatocellular carcinoma.

Axitinib/Octreotide Combo Fails to Improve PFS in Pancreatic NETs

January 17th 2021

January 17, 2021 - Axitinib plus octreotide LAR failed to demonstrate a significant improvement in progression-free survival (PFS) compared with placebo plus octreotide LAR in patients with advanced G1-2 extra-pancreatic neuroendocrine tumors.

Infigratinib Shows Promising Anticancer Activity in Chemo-Refractory, FGFR2+ Cholangiocarcinoma

January 17th 2021

January 17, 2021 - Infigratinib was found to be associated with encouraging clinical activity with a manageable safety profile in patients with chemotherapy-refractory cholangiocarcinoma whose tumors harbor FGFR2 fusions.

Ivosidenib Induces OS Benefit in Advanced IDH1+ Cholangiocarcinoma

January 17th 2021

January 17, 2021 — Ivosidenib tablets led to a 21% reduction in the risk of death compared with placebo in previously treated patients with IDH1-mutant cholangiocarcinoma, according to the final overall survival analysis of the phase 3 ClarIDHy trial.

Dr. Harding on the Results of the SUMMIT Trial in HER2+ Biliary Tract Cancers

January 17th 2021

James J. Harding, MD, discusses the results of the ongoing, phase 2 SUMMIT basket trial in HER2-mutant advanced biliary tract cancers.

Dr. Zhu on the OS Results of the ClarIDHy Trial in IDH1+ Cholangiocarcinoma

January 17th 2021

Andrew Zhu, MD, PhD, discusses the final overall survival results from the phase 3 ClarIDHy trial in previously treated patients with IDH1-mutated cholangiocarcinoma.

TAS-102 Plus Bevacizumab Improves OS in mCRC Ineligible for Intensive Therapy

January 17th 2021

January 16, 2021 - Trifluridine/tipiracil, when used in combination with bevacizumab, led to an improvement in overall survival over capecitabine/bevacizumab in the frontline treatment of patients with unresectable metastatic colorectal cancer who are not eligible for standard chemotherapy.

Dr. Wainberg on the FIGHT Trial Results in FGFR2b+ Gastric/GEJ Cancer

January 16th 2021

Zev A. Wainberg, MD, of University of California, Los Angeles, discusses the results of the phase 2 FIGHT trial (NCT03343301) in FGFR2b-positive gastric/gastroesophageal junction (GEJ) cancer.

Single-Agent Lenvatinib Shows Real-World Efficacy in Frontline HCC

January 16th 2021

January 16, 2021 - Lenvatinib monotherapy was found to be effective in patients with unresectable hepatocellular carcinoma in the United States.

Dr. Subbiah on the Clinical Activity of Pralsetinib in RET+ Cholangiocarcinoma

January 16th 2021

Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses the clinical activity of pralsetinib (Gavreto) in RET fusion-positive pancreatic cancer and cholangiocarcinoma.

Mean Daily Step Count While Receiving SM-88 Correlates With Patient-Reported QoL in Metastatic Pancreatic Cancer

January 16th 2021

January 16, 2021 - Mean daily step count during the first 2 weeks of treatment with SM-88 was found to correlate with overall self-reported quality of life in patients with metastatic pancreatic cancer.

Addition of Pembrolizumab to Chemo Does Not Negatively Impact QoL in Patients With Esophageal Cancer

January 16th 2021

January 16, 2021 - Health-related quality of life during an 18-week period proved to be similar over for patients with esophageal cancer treated with either pembrolizumab or placebo added to chemotherapy.

Frontline Pembrolizumab Improves PFS2, HRQoL in MSI-H/dMMR mCRC

January 16th 2021

January 16, 2021 - Frontline use of pembrolizumab monotherapy significantly improved progression-free survival, while demonstrating superior safety, compared with chemotherapy in patients with microsatellite-instability high/mismatch repair deficient metastatic colorectal cancer.

Frontline Bemarituzumab/mFOLFOX6 Combo Improves Survival in Advanced FGFR2b+ Gastric/GEJ Cancer

January 16th 2021

Bemarituzumab combined with mFOLFOX6 demonstrated a 56% reduction in the risk of disease progression or death compared with placebo and mFOLFOX6 as a frontline treatment in select patients with FGFR2b-positive advanced gastric or gastroesophageal junction adenocarcinoma.

Lenvatinib and Pembrolizumab Combination Safe, Effective For Multiple Gastrointestinal Cancer Types

January 15th 2021

The combination of the anti-angiogenic multikinase inhibitor lenvatinib plus the anti-PD-1 antibody pembrolizumab demonstrated promising antitumor activity and a manageable safety profile in previously treated patients with advanced gastric cancer, advanced metastatic microsatellite instability-high or mismatch repair colorectal cancer, and advanced biliary tract cancers

Health-Related Quality of Life Scores in Young CRC Survivors Are Low and Require Targeted Intervention

January 15th 2021

January 15, 2021 - As the incidence of colorectal cancer in patients under 50-years-old increases, overall health-related quality of life among younger survivors is poorer, with social and functional well-being suffering more as treatment duration grows longer.

Neoadjuvant Chemo Does Not Impact Surgical Risk in Thoracic Esophageal Cancer

January 15th 2021

Neoadjuvant chemotherapy regimens were not found to increase the risk for perioperative complications in patients who have potentially resectable advanced thoracic esophageal cancer.

Dr. Das on the Results of a Clinical Score Analysis in Patients With NETs

January 15th 2021

Satya Das, MD, MSCI, discusses the results of a clinical score analysis in patients with neuroendocrine tumors.